
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Donislecel
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes
Details : Lantidra (donislecel-jujn suspension for hepatic portal vein infusion) is an allogeneic pancreatic islet cellular therapy y indicated for the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c.
Product Name : Lantidra
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 29, 2023
Lead Product(s) : Donislecel
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Contact Us!